| P2093 | author name string | Qi Chen | |
| | Jian Ding | |
| | Yan Kang | |
| | Yuqin Fan | |
| P2860 | cites work | Antihypertensive drug therapy for mild to moderate hypertension during pregnancy | Q24200520 |
| | Development of pre-eclampsia within 4 weeks of sFlt-1/PlGF ratio > 38: comparison of performance at 31-34 vs 35-37 weeks' gestation. | Q51458630 |
| | Evaluation of metalloproteinases 2 and 9 and their inhibitors in physiologic and pre-eclamptic pregnancy. | Q51767630 |
| | Resveratrol improves delayed r-tPA treatment outcome by reducing MMPs. | Q52148119 |
| | Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. | Q52858097 |
| | sFlt-1/PlGF for prediction of early-onset pre-eclampsia: STEPS (Study of Early Pre-eclampsia in Spain). | Q54161406 |
| | Resveratrol lowers blood pressure in spontaneously hypertensive rats via calcium-dependent endothelial NO production. | Q55026202 |
| | Resveratrol reduces matrix metalloproteinases and alleviates intrahepatic cholestasis of pregnancy in rats | Q57137193 |
| | Diagnosis, Evaluation, and Management of the Hypertensive Disorders of Pregnancy | Q58623909 |
| | Nifedipine in the treatment of severe preeclampsia | Q68191782 |
| | Oral nifedipine versus intravenous labetalol for the treatment of severe hypertension in pregnancy | Q86163047 |
| | Drugs for treatment of very high blood pressure during pregnancy | Q24200974 |
| | Resveratrol and Cardiovascular Diseases | Q26752801 |
| | Effects of resveratrol in pregnancy using murine models with reduced blood supply to the uterus | Q30454735 |
| | The detection, investigation and management of hypertension in pregnancy: full consensus statement | Q33990742 |
| | The effect of resveratrol on blood pressure in a rat model of preeclampsia | Q33994926 |
| | Report of the Canadian Hypertension Society Consensus Conference: 3. Pharmacologic treatment of hypertensive disorders in pregnancy. | Q34026177 |
| | Influence of the sFlt-1/PlGF Ratio on Clinical Decision-Making in Women with Suspected Preeclampsia | Q36034800 |
| | Resveratrol ameliorates the chemical and microbial induction of inflammation and insulin resistance in human placenta, adipose tissue and skeletal muscle | Q36302354 |
| | Matrix metalloproteinases as drug targets in preeclampsia | Q36910638 |
| | Matrix metalloproteinase-9 deficiency phenocopies features of preeclampsia and intrauterine growth restriction | Q36990967 |
| | Matrix metalloproteinase-2 is elevated in midtrimester amniotic fluid prior to the development of preeclampsia | Q37322424 |
| | sFlt-1/PlGF ratio test for pre-eclampsia: an economic assessment for the UK | Q37561689 |
| | The effect of resveratrol on hypertension: A clinical trial. | Q37594126 |
| | Nifedipine versus labetalol in the treatment of hypertensive disorders of pregnancy | Q38009738 |
| | A review of oral labetalol and nifedipine in mild to moderate hypertension in pregnancy | Q38582079 |
| | Resveratrol inhibits trophoblast apoptosis through oxidative stress in preeclampsia-model rats. | Q38929137 |
| | Budget impact analysis of sFlt-1/PlGF ratio as prediction test in Italian women with suspected preeclampsia | Q38979806 |
| | Resveratrol attenuates matrix metalloproteinase-9 and -2-regulated differentiation of HTB94 chondrosarcoma cells through the p38 kinase and JNK pathways | Q38993637 |
| | Ketanserin versus dihydralazine for the treatment of severe hypertension in early-onset preeclampsia: a double blind randomized controlled trial | Q39016330 |
| | Nifedipine in myocardial ischemia, systemic hypertension, and other cardiovascular disorders | Q39744906 |
| | Resveratrol inhibits matrix metalloproteinases to attenuate neuronal damage in cerebral ischemia: a molecular docking study exploring possible neuroprotection | Q40445535 |
| | Nifedipine and its indications in obstetrics and gynecology | Q40728245 |
| | Resveratrol inhibits the release of soluble fms-like tyrosine kinase (sFlt-1) from human placenta | Q42722700 |
| | Nifedipine or hydralazine as a first-line agent to control hypertension in severe preeclampsia | Q43953626 |
| | The use of nifedipine during the postpartum period in patients with severe preeclampsia | Q45096856 |
| | Hemodynamic changes associated with intravenous infusion of the calcium antagonist verapamil in the treatment of severe gestational proteinuric hypertension | Q46649906 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 8 | |
| P921 | main subject | nifedipine | Q39111 |
| | pre-eclampsia | Q61335 |
| P304 | page(s) | 595-600 | |
| P577 | publication date | 2017-11-01 | |
| P1433 | published in | Endocrine Connections | Q27724876 |
| P1476 | title | Efficacy of resveratrol to supplement oral nifedipine treatment in pregnancy-induced preeclampsia | |
| P478 | volume | 6 | |